Table 5. Response to induction therapy... | American Society of Hematology

Table 5.

Response to induction therapy by pretreatment Pgp expression and efflux, MRP, and LRP expression

		Patient	Complete response			CR or restored chronic phase			Resistant disease
		Patient	% CR	95% CI	P	% CR or RCP	95% CI	P	% RD	95% CI	P
Pgp (MRK16)	D < 0.20	30	23	10 -42	.0071	27	12 -46	.025	53	34 -72	.18
	D ≥ 0.20	42	5	1 -16	—	12	4 -26	—	67	50 -80	—
CsA-inhibited	D < 0.25	29	21	8 -40	.030	24	10 -44	.028	52	33 -71	.0033
DiOC₂ efflux	D ≥ 0.25	43	7	1 -19	—	14	5 -28	—	67	51 -81	—
MRP	D < 0.20	59	12	5 -23	.75	17	8 -29	.81	59	46 -72	.29
	D ≥ 0.20	13	15	2 -45	—	23	5 -54	—	69	39 -91	—
LRP	D < 0.25	20	10	1 -32	.55	20	6 -44	.80	45	23 -68	.37
	D ≥ 0.25	51	14	6 -26	—	18	8 -31	—	67	52 -79	—

		Patient	Complete response			CR or restored chronic phase			Resistant disease
		Patient	% CR	95% CI	P	% CR or RCP	95% CI	P	% RD	95% CI	P
Pgp (MRK16)	D < 0.20	30	23	10 -42	.0071	27	12 -46	.025	53	34 -72	.18
	D ≥ 0.20	42	5	1 -16	—	12	4 -26	—	67	50 -80	—
CsA-inhibited	D < 0.25	29	21	8 -40	.030	24	10 -44	.028	52	33 -71	.0033
DiOC₂ efflux	D ≥ 0.25	43	7	1 -19	—	14	5 -28	—	67	51 -81	—
MRP	D < 0.20	59	12	5 -23	.75	17	8 -29	.81	59	46 -72	.29
	D ≥ 0.20	13	15	2 -45	—	23	5 -54	—	69	39 -91	—
LRP	D < 0.25	20	10	1 -32	.55	20	6 -44	.80	45	23 -68	.37
	D ≥ 0.25	51	14	6 -26	—	18	8 -31	—	67	52 -79	—

Two-tailed P for test of trend in response rate with Pgp, MRP1, or LRP expression level (MRK16), or efflux Dtreated as a quantitative (continuous) variable in simple (univariate) logistic regression, that is, without adjustment for stratification or treatment assignment.

View Large

This Feature Is Available To Subscribers Only